Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antras L; Smith M; Neary MP; Duh MSCancer 2007[Mar]; 109 (6): 1090-6BACKGROUND: Bisphosphonates have been used to treat bone metastases in hormone-refractory prostate cancer (HRPC), but certain agents have been associated with renal toxicity. For this observational study, the authors assessed the risk of renal impairment in patients with HRPC who received zoledronic acid from December 1999 to April 2005. METHODS: A comprehensive medical records review was performed in a major tertiary oncology center (n = 122 patients). The primary outcome of renal impairment was defined as an increase >or=0.5 mg/dL or >or=1.0 mg/dL over baseline creatinine value if the baseline value was <1.4 mg/dL or >or=1.4 mg/dL, respectively. A risk factor analysis was conducted using the Andersen-Gill extension to the Cox proportional hazards model. RESULTS: Renal impairment was observed in 23.8% of patients. The risk of renal impairment increased with an extended duration of zoledronic acid therapy (<6 months, 11.1%; >or=24 months, 26.3%) and previous pamidronate treatment (45.5% vs 19.0% for patients with no prior pamidronate). A significantly greater risk of renal impairment was associated with increasing age at zoledronic acid initiation, prior pamidronate use, and a history of renal disease, hypertension, or smoking (P |Aged[MESH]|Aged, 80 and over[MESH]|Bone Density Conservation Agents/*therapeutic use[MESH]|Bone Neoplasms/*drug therapy/secondary[MESH]|Diphosphonates/*therapeutic use[MESH]|Humans[MESH]|Imidazoles/*therapeutic use[MESH]|Male[MESH]|Middle Aged[MESH]|Neoplasms, Hormone-Dependent/*complications[MESH]|Prostatic Neoplasms/*complications[MESH]|Renal Insufficiency/*epidemiology[MESH]|Retrospective Studies[MESH]|Risk Factors[MESH]|Zoledronic Acid[MESH] |
